Biosimilar Clinical Development – A Strategic Lever?

biosimilar caption
Share this:
Print Friendly, PDF & Email

Biosimilars are set to reach $26B by 2020. The field has seen rapid progress in the recent years with a record pace in 2017.

 Traditionally, from small and narrowly focused disease areas and countries, the biosimilars market is now all set to expand. Patent expiries, Cost-effective medical care measures, price sensitivity, poor access to biologics and changing regulatory environment makes a prefect brew for the players to tap in maximum return on their investments in this field.

The presentation gives some key insights on the emerging biosimilars developer landscape with focus on US, EU, China, Japan, South Korea, MENA and Indian markets. Furthermore, it provides a detailed analysis on Clinical differentiation of players for major products (Bevacizumab, Trastuzumab, Adalimumab, Rituximab, Infliximab and etanercept).

 It is an attempt to shed some light on the future of biosimilars – “Are we looking at Semi-branded or Commoditization”

Related Post

Richa Agrawal
Richa Agrawal
Richa leads the biosimilar practice at RAS. Having followed the evolution of biosimilar industry in last five years, she has acquired relevant understanding of this space which she like to share in her posts.

Leave a Reply

Your email address will not be published. Required fields are marked *